Gottfried von Keudell, MD, PhD

About Me

I am a hematologic oncologist who cares for people with all types of lymphoma. I have special expertise in the development of new treatments for these conditions through clinical trials research.

During my training, I was fascinated by cancer biology and was inspired by the pursuit of new approaches that hold promise for improved outcomes and a better quality of life for people with blood cancers. I am currently the principal investigator of several clinical trials evaluating new lymphoma treatments, either as single agents or in combination with immunotherapy.

Patients often ask me if their disease is treatable. For most people, the answer is yes, thanks to the explosion of promising new targeted treatments, immunotherapies, and supportive care options that we have seen in recent years. I am fortunate to be part of a team that has led to some of these breakthroughs.

I believe that every person in my care deserves my full attention and dedication so that they feel supported and cared for during a difficult time in their lives. My goal is to convey a sense of hope and confidence to ease the anxiety that comes with a diagnosis of lymphoma.

Outside of work I enjoy playing the piano, being outdoors with my dog, and attending cultural events.

  • Clinical Expertise: Hodgkin and Non-Hodgkin Lymphomas; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia
  • Languages Spoken: English; German; Spanish
  • Education: MD, PhD, University of Hamburg, Germany
  • Residencies: Internal Medicine - University of Chicago
  • Fellowships: Hematology/Oncology - University of Chicago
  • Board Certifications: Internal Medicine; Hematology; Oncology

See My Colleagues


Kappa restricted Chronic Lymphocytic Leukemia and Lambda restricted plasma cell dyscrasia causing AL amyloidosis. von Keudell G, Sanchorawala V, Seldin DC, Sloan JM (2014) Amyloid. 21(2):124-7.

PET/CT imaging of a patient with several myeloid sarcomas with FLT3-ITD and NPM1 mutations. Gottfried von Keudell and Richard A. Larson (2014) J Clin Oncol. Apr 14.

PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Deng X, von Keudell G, Suzuki T, Dohmae N, Nakakido M, Piao L, Yoshioka Y, Nakamura Y, Hamamoto R. Oncotarget. 2015 Nov 3; 6(34):35173-82.

Cost-effectiveness analysis of consolidation with brentuximab-vedotin for high-risk Hodgkin lymphoma following autologous stem cell transplantation. Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S, Cancer 2017 Oct 1;123(19):3763-3771.

Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma, Huntington S, von Keudell G, Davidoff A, Gross, C, and Prasad S, in review.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.